Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


08.08.2022

1 Aging (Albany NY)
1 Am J Clin Pathol
1 Am J Gastroenterol
1 Anticancer Res
1 Biochem Biophys Res Commun
1 Biochem Cell Biol
1 BJU Int
1 BMC Genom Data
2 BMC Urol
1 Cancer Cytopathol
1 Cancer Discov
1 Cancer Gene Ther
1 Cancer Med
1 Clin Cancer Res
9 Curr Opin Urol
1 Diagn Cytopathol
2 Dis Markers
1 Environ Health Perspect
1 Eur J Epidemiol
1 Eur Urol Focus
5 Eur Urol Oncol
1 Front Cell Dev Biol
1 Front Genet
1 Front Immunol
1 Front Mol Biosci
5 Front Oncol
1 Front Pharmacol
1 Front Surg
1 Int J Cancer
1 Int J Med Sci
1 Int J Mol Sci
1 Integr Cancer Ther
1 J Adv Res
1 J Cell Physiol
1 J Clin Lab Anal
1 J Immunol Res
1 J Inflamm Res
1 J Med Imaging Radiat Oncol
1 JCI Insight
1 Med J Malaysia
1 Medicina (B Aires)
2 Pathol Res Pract
1 Scand J Urol
5 Urol Int
1 Urol Oncol
1 Urologie
3 Urology
1 Virchows Arch


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aging (Albany NY)

  1. TANG Z, Tang C, Sun C, Ying X, et al
    M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine.
    Aging (Albany NY). 2022;14.
    PubMed         Abstract available


    Am J Clin Pathol

  2. ZALESKI MP, Chen H, Roy-Chowdhuri S, Patel KP, et al
    Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.
    Am J Clin Pathol. 2022;158:263-269.
    PubMed         Abstract available


    Am J Gastroenterol

  3. OKAMOTO T, Yamamoto K, Kanomata N
    Correction to: Metastatic Rectal Linitis Plastica From Bladder Cancer.
    Am J Gastroenterol. 2022;117:1336.
    PubMed        


    Anticancer Res

  4. VASSILIOU V, Katsila T, Sodergren SC, Kardamakis D, et al
    Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications.
    Anticancer Res. 2022;42:3767-3778.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  5. XU Y, Lei Z, Zhu J, Wan L, et al
    Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway.
    Biochem Biophys Res Commun. 2022;623:120-126.
    PubMed         Abstract available


    Biochem Cell Biol

  6. LIU T, Zhang Z, Wang C, Huang H, et al
    Correction: BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance.
    Biochem Cell Biol. 2022;100:274-275.
    PubMed        


    BJU Int

  7. JAMES ND, Liu W, Pirrie S, Kaur B, et al
    TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.
    BJU Int. 2022 Jul 31. doi: 10.1111/bju.15864.
    PubMed         Abstract available


    BMC Genom Data

  8. ZHU Q, Zhang L, Deng Y, Tang L, et al
    Identification of immune-related and autophagy-related genes for the prediction of survival in bladder cancer.
    BMC Genom Data. 2022;23:60.
    PubMed         Abstract available


    BMC Urol

  9. XIANG AP, Chen XN, Xu PF, Shao SH, et al
    Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma.
    BMC Urol. 2022;22:120.
    PubMed         Abstract available

  10. WANG J, Tuo Z, Gao M, Min J, et al
    Is it necessary to perform a retrosigmoid transposition of the left ureter in Bricker Ileal Conduit surgery?
    BMC Urol. 2022;22:116.
    PubMed         Abstract available


    Cancer Cytopathol

  11. KIM D, Burkhardt R, Alperstein SA, Gokozan HN, et al
    Evaluating the role of Z-stack to improve the morphologic evaluation of urine cytology whole slide images for high-grade urothelial carcinoma: Results and review of a pilot study.
    Cancer Cytopathol. 2022;130:630-639.
    PubMed         Abstract available


    Cancer Discov

  12. GOUBET AG, Lordello L, Alves Costa Silva C, Peguillet I, et al
    Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer.
    Cancer Discov. 2022 Aug 5. pii: 707463. doi: 10.1158/2159-8290.CD-22-0201.
    PubMed         Abstract available


    Cancer Gene Ther

  13. LIU Q, You B, Meng J, Huang CP, et al
    Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.
    Cancer Gene Ther. 2022 Aug 1. pii: 10.1038/s41417-022-00506.
    PubMed         Abstract available


    Cancer Med

  14. KARASHIMA T, Umemoto S, Kishida T, Osaka K, et al
    Clinical evaluation of urine laminin-gamma2 monomer as a potent biomarker for non-muscle invasive bladder cancer.
    Cancer Med. 2022 Aug 4. doi: 10.1002/cam4.5087.
    PubMed         Abstract available


    Clin Cancer Res

  15. ZHU Z, Ma AH, Zhang H, Lin TY, et al
    Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer.
    Clin Cancer Res. 2022 Aug 3. pii: 707432. doi: 10.1158/1078-0432.CCR-22-1362.
    PubMed         Abstract available


    Curr Opin Urol

  16. ESCOTT M, Avulova S, Bree KK, Westerman ME, et al
    Radical cystectomy and women's sexual health - can we do better?
    Curr Opin Urol. 2022;32:545-553.
    PubMed         Abstract available

  17. PIJPERS OM, de Jong JJ, Zuiverloon TCM, Boormans JL, et al
    RNA-based urinary assays for non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022;32:523-530.
    PubMed         Abstract available

  18. COMPERAT E, Oszwald A, Wasinger G, Klager J, et al
    Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis.
    Curr Opin Urol. 2022;32:451-455.
    PubMed         Abstract available

  19. LAUKHTINA E, Pradere B, Lemberger U, Karakiewicz PI, et al
    Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
    Curr Opin Urol. 2022;32:561-566.
    PubMed         Abstract available

  20. SHEYBAEE MOGHADDAM F, Ghoreifi A, Djaladat H
    Comparative performance of the different orthotopic urinary diversions.
    Curr Opin Urol. 2022;32:554-560.
    PubMed         Abstract available

  21. KIM SH, Lerner SP
    Drug instillation in the management of urinary tract urothelial carcinoma.
    Curr Opin Urol. 2022;32:531-535.
    PubMed         Abstract available

  22. MESSINA E, Pisciotti ML, Pecoraro M, Borrelli A, et al
    The use of MRI in urothelial carcinoma.
    Curr Opin Urol. 2022;32:536-544.
    PubMed         Abstract available

  23. COMPERAT E, Wasinger G, Oszwald A, Shariat SF, et al
    Brief update of the new WHO classification for urothelial carcinoma.
    Curr Opin Urol. 2022;32:511-516.
    PubMed         Abstract available

  24. MARTINI A, Fallara G, Ploussard G, Pradere B, et al
    Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma.
    Curr Opin Urol. 2022;32:500-503.
    PubMed         Abstract available


    Diagn Cytopathol

  25. WANG BG, Woodward K, Menezes G, Wang ZQ, et al
    Pleural fluid metastasis of plasmacytoid urothelial carcinoma in comparison to micropapillary and conventional high-grade urothelial carcinoma: Cytologic and immuonohistochemical findings.
    Diagn Cytopathol. 2022;50:E248-E254.
    PubMed         Abstract available


    Dis Markers

  26. ZHAO X, Hu J, Li J, Gu L, et al
    THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer.
    Dis Markers. 2022;2022:7147279.
    PubMed         Abstract available

  27. HE L, Yang B, Jian D, Luo H, et al
    Prognostic Value of HPV E6 and APOBEC3B in Upper Urinary Tract Urothelial Carcinoma.
    Dis Markers. 2022;2022:2147494.
    PubMed         Abstract available


    Environ Health Perspect

  28. WEISMAN RJ, Heinrich A, Letkiewicz F, Messner M, et al
    Estimating National Exposures and Potential Bladder Cancer Cases Associated with Chlorination DBPs in U.S. Drinking Water.
    Environ Health Perspect. 2022;130:87002.
    PubMed         Abstract available


    Eur J Epidemiol

  29. COSCIA C, Gill D, Benitez R, Perez T, et al
    Avoiding collider bias in Mendelian randomization when performing stratified analyses.
    Eur J Epidemiol. 2022;37:671-682.
    PubMed         Abstract available


    Eur Urol Focus

  30. KIM YS, Hsieh AC, Lam HM
    Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.
    Eur Urol Focus. 2022 Jul 29. pii: S2405-4569(22)00166.
    PubMed         Abstract available


    Eur Urol Oncol

  31. GALLIOLI A, Diana P, Fontana M, Territo A, et al
    En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial.
    Eur Urol Oncol. 2022;5:440-448.
    PubMed         Abstract available

  32. LENFANT L, Breda A, Xylinas E, Babjuk M, et al
    Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma.
    Eur Urol Oncol. 2022;5:464-471.
    PubMed         Abstract available

  33. SORIA F, Gontero P
    Intermediate-risk Non-muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?
    Eur Urol Oncol. 2022 Jul 27. pii: S2588-9311(22)00115.
    PubMed        

  34. STENZL A
    En Bloc Resection of Bladder Tumours: Ready for Clinical Use?
    Eur Urol Oncol. 2022;5:449-450.
    PubMed        

  35. MARTINI A, Lonati C, Nocera L, Fallara G, et al
    Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma.
    Eur Urol Oncol. 2022;5:451-459.
    PubMed         Abstract available


    Front Cell Dev Biol

  36. TAN J, Wang Y, Sun L, Xu S, et al
    The Origin and Evolution of Bladder Cancer Stem Cells.
    Front Cell Dev Biol. 2022;10:950241.
    PubMed         Abstract available


    Front Genet

  37. TANG D, Li Y, Tang Y, Zheng H, et al
    Recognition of Glycometabolism-Associated lncRNAs as Prognosis Markers for Bladder Cancer by an Innovative Prediction Model.
    Front Genet. 2022;13:918705.
    PubMed         Abstract available


    Front Immunol

  38. OU SL, Luo J, Wei H, Qin XL, et al
    Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.
    Front Immunol. 2022;13:953761.
    PubMed         Abstract available


    Front Mol Biosci

  39. SU Z, Monshaugen I, Klungland A, Ougland R, et al
    Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow.
    Front Mol Biosci. 2022;9:887686.
    PubMed         Abstract available


    Front Oncol

  40. ZHANG Z, Li X, Ren S, Zhang W, et al
    CNN1 Represses Bladder Cancer Progression and Metabolic Reprogramming by Modulating HIF-1alpha Signaling Pathway.
    Front Oncol. 2022;12:859707.
    PubMed         Abstract available

  41. LI DX, Wang XM, Feng DC, Zhang FC, et al
    Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer.
    Front Oncol. 2022;12:937638.
    PubMed         Abstract available

  42. CHENG X, Lou K, Ding L, Zou X, et al
    Clinical potential of the Hippo-YAP pathway in bladder cancer.
    Front Oncol. 2022;12:925278.
    PubMed         Abstract available

  43. ZHU Z, Xiao Y, Hu S, Wang Z, et al
    Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis.
    Front Oncol. 2022;12:907454.
    PubMed         Abstract available

  44. CHEN T, Zhan X, Chen X, Jiang M, et al
    Predictive Value of the Log Odds of Negative Lymph Nodes/T Stage as a Novel Prognostic Factor in Bladder Cancer Patients After Radical Cystectomy.
    Front Oncol. 2022;12:895413.
    PubMed         Abstract available


    Front Pharmacol

  45. CHENG Z, Ye F, Xu C, Liang Y, et al
    The potential mechanism of Longsheyangquan Decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking.
    Front Pharmacol. 2022;13:932039.
    PubMed         Abstract available


    Front Surg

  46. GUO M, Li Y, Wang W, Kang X, et al
    Variation of Anxiety and Depression During a 3-Year Period as Well as Their Risk Factors and Prognostic Value in Postoperative Bladder Cancer Patients.
    Front Surg. 2022;9:893249.
    PubMed         Abstract available


    Int J Cancer

  47. XIONG J, Yang L, Deng YQ, Yan SY, et al
    The causal association between smoking, alcohol consumption and risk of bladder cancer: A univariable and multivariable Mendelian randomization study.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34228.
    PubMed         Abstract available


    Int J Med Sci

  48. CHOI NR, Choi WG, Kwon MJ, Woo JH, et al
    [6]-Gingerol induces Caspase-Dependent Apoptosis in Bladder Cancer cells via MAPK and ROS Signaling.
    Int J Med Sci. 2022;19:1093-1102.
    PubMed         Abstract available


    Int J Mol Sci

  49. MONTES-MOJARRO IA, Hassas S, Staehle S, Sander P, et al
    Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available


    Integr Cancer Ther

  50. HWANG B, Gho Y, Kim H, Lee S, et al
    Rosa hybrida Petal Extract Exhibits Antitumor Effects by Abrogating Tumor Progression and Angiogenesis in Bladder Cancer Both In Vivo and In Vitro.
    Integr Cancer Ther. 2022;21:15347354221114337.
    PubMed         Abstract available


    J Adv Res

  51. GELBRICH N, Miebach L, Berner J, Freund E, et al
    Non-invasive medical gas plasma augments bladder cancer cell toxicity in preclinical models and patient-derived tumor tissues.
    J Adv Res. 2022 Aug 2. pii: S2090-1232(22)00166.
    PubMed         Abstract available


    J Cell Physiol

  52. TSAI TF, Chang AC, Chen PC, Ho CY, et al
    Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer.
    J Cell Physiol. 2022 Jul 29. doi: 10.1002/jcp.30817.
    PubMed         Abstract available


    J Clin Lab Anal

  53. SETTI BOUBAKER N, Gurtner A, Trabelsi N, Manni I, et al
    An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.
    J Clin Lab Anal. 2022 Jul 19:e24606. doi: 10.1002/jcla.24606.
    PubMed         Abstract available


    J Immunol Res

  54. LUO H, Liu GL, Jian D, Liang DD, et al
    Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.
    J Immunol Res. 2022;2022:9962397.
    PubMed         Abstract available


    J Inflamm Res

  55. GAO M, Yang Q, Xu H, Chen Z, et al
    Preoperative White Blood Cell-Related Indicators Can Predict the Prognosis of Patients with Transurethral Resection of Bladder Cancer.
    J Inflamm Res. 2022;15:4139-4147.
    PubMed         Abstract available


    J Med Imaging Radiat Oncol

  56. FERNANDES MC, Shoushtari A, Leitao MM Jr, Chui MH, et al
    Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report.
    J Med Imaging Radiat Oncol. 2022;66:643-646.
    PubMed         Abstract available


    JCI Insight

  57. REHMAN H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, et al
    ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
    JCI Insight. 2022 Jul 19. pii: 155899. doi: 10.1172/jci.insight.155899.
    PubMed         Abstract available


    Med J Malaysia

  58. RINONCE HT, Ambarwati THD, Syaebani M, Pudjohartono MF, et al
    Assessment of association between PD-L1 expression and clinicopathological characteristics of Indonesian patients with high grade bladder urothelial carcinoma.
    Med J Malaysia. 2022;77.
    PubMed         Abstract available


    Medicina (B Aires)

  59. NAZAR M, Sabatella A, Ficalora G, Troncoso Y, et al
    [Rectal metastasis of a resected urothelial bladder cancer].
    Medicina (B Aires). 2022;82:609-612.
    PubMed         Abstract available


    Pathol Res Pract

  60. MARCHESE PV, Mollica V, De Biase D, Giunchi F, et al
    A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
    Pathol Res Pract. 2022;236:153983.
    PubMed         Abstract available

  61. LEDDEROSE S, Rodler S, Eismann L, Ledderose G, et al
    Tumor-infiltrating lymphocytes predict survival in >/= pT2 urothelial bladder cancer.
    Pathol Res Pract. 2022;237:154037.
    PubMed         Abstract available


    Scand J Urol

  62. MAY M, Wolff I, Brookman-May SD, Burger M, et al
    Bladder cancer with secondary muscle invasion - a prognostic dilemma.
    Scand J Urol. 2022 Aug 3:1-2. doi: 10.1080/21681805.2022.2107068.
    PubMed        


    Urol Int

  63. STOKKEL LE, van de Kamp MW, Schaake EE, Boellaard TN, et al
    Robot-Assisted Partial Cystectomy versus Open Partial Cystectomy for Patients with Urachal Cancer.
    Urol Int. 2022;106:840-847.
    PubMed         Abstract available

  64. NIENTIEDT M, Waldbillig F, Stroop F, Nuhn P, et al
    Upper Tract Urinary Cancer Recurrence after Radical Cystectomy: Risk Assessment of Intraoperative Frozen Section.
    Urol Int. 2022;106:816-824.
    PubMed         Abstract available

  65. DREGER NM, Lohbeck A, Roth S, Godde D, et al
    Effectiveness and Safety of a Modified Technique of Transvesical Obturator Nerve Block to Avoid Adductor Contractions during Transurethral Resection of Bladder Tumors.
    Urol Int. 2022;106:775-783.
    PubMed         Abstract available

  66. SCHNEIDEWIND L, Torabi L, Drager DL, Hakenberg OW, et al
    Reduction of Perioperative Antibiotic Prophylaxis in Open Radical Cystectomy with Ileal Conduit Is Feasible: Results of a Prospective Clinical Trial.
    Urol Int. 2022;106:825-831.
    PubMed         Abstract available

  67. CILESIZ NC, Ozkan A, Kalkanli A, Gezmis CT, et al
    Spinal Anesthesia Provides Longer Administration Time for Postoperative Intravesical Chemotherapy after TUR-B Operation.
    Urol Int. 2022;106:768-774.
    PubMed         Abstract available


    Urol Oncol

  68. KRAJEWSKI W, Aumatell J, Subiela JD, Nowak L, et al
    Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
    Urol Oncol. 2022 Jul 15. pii: S1078-1439(22)00227.
    PubMed         Abstract available


    Urologie

  69. GUZVIC M, Engelmann S, Burger M, Mayr R, et al
    [Disseminated tumour cells in bladder cancer].
    Urologie. 2022;61:728-733.
    PubMed         Abstract available


    Urology

  70. ELSAYED AS, Iqbal U, Jing Z, Houenstein HA, et al
    Relapses Rates and Patterns for Pathological T0 After Robot-Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium.
    Urology. 2022;166:177-181.
    PubMed         Abstract available

  71. MITCHELL K, Elbakry AA, Naili RE, Al-Omar O, et al
    Dysfunctional Voiding- Presentation of a Rare Case of Pediatric Non Muscle Invasive Urothelial Bladder Carcinoma.
    Urology. 2022;166:233-235.
    PubMed         Abstract available

  72. SHUMAKER L, Nocera A, Selph P
    Enhanced Recovery After Surgery in the Urinary Diversion Population: Are Protocols Applied Differently in the Benign Indication Population?
    Urology. 2022;166:50-55.
    PubMed         Abstract available


    Virchows Arch

  73. QUEIPO FJ, Unamunzaga GM, Negro BF, Fuertes SG, et al
    Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Virchows Arch. 2022;481:191-200.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: